Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 647 press releases before 2018
-
AstraZeneca enters agreement with Cilag GmbH International to divest rights to Rhinocort Aqua outside the US
-
AstraZeneca enters agreement with Aralez for beta-blocker medicine Toprol-XL in the US
-
AstraZeneca reports top-line results from the Brilinta EUCLID trial in patients with peripheral artery disease
-
MedImmune out-licenses potential medicine for inflammatory diseases to Allergan
-
AstraZeneca presents new data on Faslodex in breast cancer and provides immuno-oncology update at ESMO 2016 congress
-
AstraZeneca provides update on cediranib EU marketing authorisation application
-
Phase III combination trial of Bydureon and Forxiga shows significant benefits in patients with type-2 diabetes
-
AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure
-
PEPFAR and AstraZeneca launch partnership across HIV and hypertension services in Africa
-
Benralizumab phase III trials show positive results in severe asthma
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Gonzalo Viña
Head of Global Media Relations
+44 203 749 5916
Rob Skelding
Director Global Media Relations (Oncology)
+44 203 749 5821
Rebecca Einhorn
Director Global Media Relations (Oncology)
+1 301 398 1802
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 203 749 5906
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 122 334 4690
Jennifer Hursit
Manager Global Media Relations
+44 203 749 5762
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
